Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
1996
1.4K+
LTM Revenue $273M
LTM EBITDA $75.3M
$733M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of November 2025, Equasens reported last 12-month revenue of $273M and EBITDA of $75.3M.
In the same period, Equasens achieved $45.5M in LTM net income.
See Equasens valuation multiples based on analyst estimatesIn the most recent fiscal year, Equasens reported revenue of $252M and EBITDA of $73.2M.
Equasens expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Equasens valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $273M | XXX | $252M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $173M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $75.3M | XXX | $73.2M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $56.3M | XXX | $52.7M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $45.5M | XXX | $42.1M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $37.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Equasens has current market cap of EUR 622M (or $724M), and EV of EUR 631M (or $733M).
As of December 5, 2025, Equasens's stock price is EUR 41 (or $48).
See Equasens trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $733M | $724M | XXX | XXX | XXX | XXX | $3.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialEquasens's trades at 2.9x EV/Revenue multiple, and 10.0x EV/EBITDA.
See valuation multiples for Equasens and 15K+ public compsAs of December 5, 2025, Equasens has market cap of $724M and EV of $733M.
Equity research analysts estimate Equasens's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Equasens has a P/E ratio of 15.9x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $724M | XXX | $724M | XXX | XXX | XXX |
| EV (current) | $733M | XXX | $733M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBIT | 13.0x | XXX | 13.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.9x | XXX | 17.2x | XXX | XXX | XXX |
| EV/FCF | 14.1x | XXX | 17.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEquasens's last 12 month revenue growth is 8%
Equasens's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Equasens's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Equasens's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Equasens and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | -5% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Apiam Animal Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Artrya | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Equasens acquired XXX companies to date.
Last acquisition by Equasens was XXXXXXXX, XXXXX XXXXX XXXXXX . Equasens acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Equasens founded? | Equasens was founded in 1996. |
| Where is Equasens headquartered? | Equasens is headquartered in France. |
| How many employees does Equasens have? | As of today, Equasens has 1.4K+ employees. |
| Who is the CEO of Equasens? | Equasens's CEO is Mr. Denis Supplisson. |
| Is Equasens publicy listed? | Yes, Equasens is a public company listed on PAR. |
| What is the stock symbol of Equasens? | Equasens trades under EQS ticker. |
| When did Equasens go public? | Equasens went public in 2000. |
| Who are competitors of Equasens? | Similar companies to Equasens include e.g. Apiam Animal Health, Alcidion Group, Artrya, CurveBeam AI. |
| What is the current market cap of Equasens? | Equasens's current market cap is $724M |
| What is the current revenue of Equasens? | Equasens's last 12 months revenue is $273M. |
| What is the current revenue growth of Equasens? | Equasens revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Equasens? | Current revenue multiple of Equasens is 2.7x. |
| Is Equasens profitable? | Yes, Equasens is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Equasens? | Equasens's last 12 months EBITDA is $75.3M. |
| What is Equasens's EBITDA margin? | Equasens's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Equasens? | Current EBITDA multiple of Equasens is 9.7x. |
| What is the current FCF of Equasens? | Equasens's last 12 months FCF is $51.9M. |
| What is Equasens's FCF margin? | Equasens's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Equasens? | Current FCF multiple of Equasens is 14.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.